Insurer, Insured Costs for HIV PrEP Rising in the United States
WEDNESDAY, Sept. 9, 2020 -- From 2014 to 2018, there were increases noted in third-party and out-of-pocket (OOP) payments per 30 tenofovir disoproxil fumarate with emtricitabine (TDF-FTC) tablets for HIV preexposure prophylaxis (PrEP), according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 9, 2020 Category: Pharmaceuticals Source Type: news

' Vacation PrEP': Short-Term HIV Prevention a Viable Option
THURSDAY, Aug. 27, 2020 -- The daily use of antiretroviral meds to help prevent HIV infection has been around for a few years now -- it's called pre-exposure prophylaxis, or PrEP. PrEP includes combo drugs such as Truvada (tenofovir/emtricitabine).... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 27, 2020 Category: General Medicine Source Type: news

Renal Dysfunction Improves Following Tenofovir Type Switch: Study Renal Dysfunction Improves Following Tenofovir Type Switch: Study
In HIV/HBV-coinfected individuals with renal dysfunction, renal function improves after switching from tenofovir disoproxil fumarate to tenofovir alafenamide, according to results from a prospective study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 19, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Weight Gain Persists as HIV-Treatment Issue Weight Gain Persists as HIV-Treatment Issue
Reports have rattled the HIV-treatment community by associating alarmingly high levels of weight gain with a useful and relatively new drug, tenofovir alafenamide fumarate.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 7, 2020 Category: Endocrinology Tags: Infectious Diseases News Source Type: news

Switching TDF to TAF in a Real Life Setting Switching TDF to TAF in a Real Life Setting
Are there benefits to an ART switch from tenofovir disoproxil fumarate to tenofovir alafenamide?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 10, 2020 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

HPTN 083 study demonstrates superiority of cabotegravir for the prevention of HIV
(FHI360) The HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every 8 weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention among cisgender men and transgender women who have sex with men. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 7, 2020 Category: Infectious Diseases Source Type: news

Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
Title: Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)Category: MedicationsCreated: 4/17/2020 12:00:00 AMLast Editorial Review: 4/17/2020 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - April 17, 2020 Category: Infectious Diseases Source Type: news

Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide)
Title: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide)Category: MedicationsCreated: 4/16/2020 12:00:00 AMLast Editorial Review: 4/16/2020 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - April 16, 2020 Category: Infectious Diseases Source Type: news

Safety of TAF in Patients With Tubulopathy on TDF Safety of TAF in Patients With Tubulopathy on TDF
Is tenofovir alafenamide a safe and effective option for HIV patients with a history of tenofovir disoproxil fumarate-associated tubulopathy?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 25, 2020 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2
Anecdotal, unsubstantiated reports claim that darunavir has antiviral effect against COVID-19Johnson & Johnson has no evidence that darunavir has any effect against SARS-CoV-2, the virus that causes COVID-19Johnson & Johnson is screening its antiviral compounds, including darunavir, to determine potential in vitro effect against SARS-CoV-2We are partnering with multiple organizations to support the development of research programs and fast-track solutions for COVID-19Considering the large public health and humanitarian implications, we are committed to global efforts to care for those affected, contain the current ...
Source: Johnson and Johnson - March 16, 2020 Category: Pharmaceuticals Tags: Corporate Source Type: news

New HIV PrEP Drug Not Cost-Effective Compared With Generic
WEDNESDAY, March 11, 2020 -- Use of tenofovir alafenamide-emtricitabine (F/TAF) is not cost-effective compared with generic tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) among men who have sex with men... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2020 Category: Pharmaceuticals Source Type: news

Newer anti-HIV drugs safest, most effective during pregnancy
(NIH/National Institute of Allergy and Infectious Diseases) The antiretroviral drugs dolutegravir and emtricitabine/tenofovir alafenamide fumarate (DTG+FTC/TAF) may comprise the safest and most effective HIV treatment regimen currently available during pregnancy, researchers announced today. Their findings come from a multinational study of more than 640 pregnant women with HIV across four continents. The current study compared three antiretroviral drug regimens and found that regimens containing dolutegravir (DTG) were more effective in suppressing HIV than a commonly used regimen containing efavirenz (EFV). (Source: Eure...
Source: EurekAlert! - Medicine and Health - March 11, 2020 Category: International Medicine & Public Health Source Type: news

NIH study finds lower concentration of PrEP drug in pregnant young women
(NIH/National Institute of Allergy and Infectious Diseases) Among African adolescent girls and young women who took HIV pre-exposure prophylaxis (PrEP) daily, levels of the PrEP drug tenofovir were more than 30% lower in those who were pregnant than in those who had recently given birth. All 40 study participants took PrEP under direct observation, confirming their near-perfect adherence. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 9, 2020 Category: International Medicine & Public Health Source Type: news

Emtricitabine/tenofovir alafenamide not cost effective despite fewer AEs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2020 Category: Drugs & Pharmacology Source Type: news

NPPA seeks clarification on Gilead's drug pricing plea
National Pharmaceutical Pricing Authority has sought clarifications from the company. Gilead had sought exemption from price control for its Tenofovir Alafenamide tablets (brand name Vemlidy) to capture a major chunk of Rs 140-crore market for chronic Hepatitis B in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 31, 2020 Category: Pharmaceuticals Source Type: news

D/C/F/TAF Tablet Effective Rapid-Initiation HIV Treatment D/C/F/TAF Tablet Effective Rapid-Initiation HIV Treatment
The single-tablet combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is effective for treating newly diagnosed HIV-1 infection before baseline laboratory results are available, according to results from the DIAMOND phase-3 study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 21, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Four-Drug Combination Effective Long-Term for HIV Suppression Four-Drug Combination Effective Long-Term for HIV Suppression
The single-tablet combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is effective for long-term viral suppression in previously untreated patients with HIV-1 infection, according to 96-week results from the AMBER trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 3, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Nigeria: HIV - Experts Urge Increased Awareness On Anti-Retroviral Drug
[Daily Trust] Experts have called for increased enlightenment on the anti- retroviral drug, Tenofovir/Lamivudine/Dolutegravir (TLD). (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - December 30, 2019 Category: Infectious Diseases Source Type: news

Activists and LGBTQ Groups Say These Facebook Ads Spread Dangerous Misinformation About HIV Drugs
Advocacy groups are urging Facebook to remove advertisements that they say unfairly infer that the HIV/AIDS prevention Truvada PrEP (pre-exposure prophylaxis) is dangerous, an allegation they say could endanger the people who are most at risk of contracting the disease. More than 50 HIV/AIDs, LGBTQ and public health advocacy groups released a letter on Monday asking Facebook and Instagram to remove the ads from their platforms. The ads referred specifically to “Truvada PrEP” (the brand name for one of the medications, dtenofovir disoproxil fumarate, used as PrEP) and in some cases more generically to “PrE...
Source: TIME: Health - December 11, 2019 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized health LGBTQ onetime Source Type: news

FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) indication for Descovy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 4, 2019 Category: Drugs & Pharmacology Source Type: news

FDA OKs Descovy, Second Drug for HIV PrEP FDA OKs Descovy, Second Drug for HIV PrEP
The combo of emtricitabine and tenofovir alafenamide is indicated to reduce the risk for HIV-1 infection from sex (excluding receptive vaginal sex) in at-risk adults and teens weighing at least 35 kg.FDA Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 3, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
The U.S. Food and Drug Administration today approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. (Source: World Pharma News)
Source: World Pharma News - October 3, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Delstrigo (Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 30, 2019 Category: Drugs & Pharmacology Source Type: news

Merck ’s Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed
KENILWORTH, N.J.--(BUSINESS WIRE) September 20, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications (sNDAs) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 20, 2019 Category: Drugs & Pharmacology Source Type: news

Weight Gain on INSTI-based HIV Antiretrovirals Weight Gain on INSTI-based HIV Antiretrovirals
Dolutegravir and tenofovir alafenamide can lead to weight gain, especially in women, according to new data that are changing the way researchers look at their study populations.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 26, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Minor Changes in BMD Seen With Tenofovir PrEP in Short Term
WEDNESDAY, July 24, 2019 -- Tenofovir preexposure prophylaxis (PrEP) therapy does not appear to be associated with clinically significant declines in bone mineral density (BMD) in the short term, according to a study published online June 19 in AIDS... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 25, 2019 Category: Pharmaceuticals Source Type: news

Lower than expected risk of bone density decline with Truvada PrEP
(Mary Ann Liebert, Inc./Genetic Engineering News) Researchers have shown that among users of pre-exposure prophylaxis (PrEP) to prevent against AIDS that includes tenofovir (Truvada), those with daily use -- very high adherence -- had only about a 1% average decrease in bone mineral density in the spine and a 0.5% decline in the hip. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2019 Category: International Medicine & Public Health Source Type: news

Zambia: Govt Gets TAF On HIV
[Times of Zambia] The government has launched a new HIV drug called Tenofovir Alafenamide (TAF) which is said to have fewer side effects on bones and kidney and can suppress viral loads within 10-14 days. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - July 2, 2019 Category: Infectious Diseases Source Type: news

Biktarvy (Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2019 Category: Drugs & Pharmacology Source Type: news

For the First Time, an Expert Panel Is Recommending a Drug to Prevent High-Risk Groups From Getting HIV
Over the past few decades, doctors and researchers have made admirable progress in controlling the spread of HIV, mainly by using anti-HIV drugs in powerful combinations that can make it harder for the virus to infect cells and pump out more copies of itself. But as any infectious-disease expert knows, preventing new infections is equally as important as treating existing cases to contain an epidemic. And in the U.S. each year, nearly 40,000 people are still newly diagnosed with HIV. With its latest recommendation, published in JAMA, the U.S. Preventive Services Task Force (USPSTF) issued its strongest strategy yet for pre...
Source: TIME: Health - June 11, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized HIV hiv prevention Infectious Disease Source Type: news

Bictegravir-Based Regimen Noninferior to Dolutegravir-Based Regimens for HIV Treatment Bictegravir-Based Regimen Noninferior to Dolutegravir-Based Regimens for HIV Treatment
A single-tablet regimen of bictegravir, emtricitabine and tenofovir alafenamide is noninferior to regimens of dolutegravir coformulated with emtricitabine and tenofovir alafenamide or with abacavir and lamivudine for the initial treatment of HIV-1 infection, according to results from two randomized phase 3 trials.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - June 7, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Reanalysis of Tenofovir Study Changes Some Findings Reanalysis of Tenofovir Study Changes Some Findings
A reanalysis of a study comparing outcomes with tenofovir and entecavir for chronic hepatitis B has yielded different results, with some findings no longer statistically significant, researchers from South Korea report.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - May 15, 2019 Category: Transplant Surgery Tags: Infectious Diseases News Source Type: news

Transgender Females Have Lower Tenofovir Diphosphate Concentrations Transgender Females Have Lower Tenofovir Diphosphate Concentrations
Transgender females taking feminizing hormone therapy (FHT) have lower effective rectal tissue concentrations of tenofovir diphosphate active metabolites, compared with cisgender women and men, researchers report.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 13, 2019 Category: Infectious Diseases Tags: Diabetes & Endocrinology News Source Type: news

Zimbabwe: New Combined HIV First Liners Drug Introduced in Zimbabwe
[263Chat] MYLAN together with New Avakash have introduced a new drug called Tenofovir alafenamide (TAF) meant to assist first liners on ARV treatment in Zimbabwe. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 6, 2019 Category: African Health Source Type: news

Hepatitis B virus infection in children and adolescents
This Series paper summarises knowledge on epidemiology, natural history, and treatment, and highlights key differences from infection acquired in adulthood. It discusses treatment options entecavir and tenofovir, recommending conservative approach to treatment initiation. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 25, 2019 Category: Consumer Health News Source Type: news

Temixys (Lamivudine and Tenofovir Disoproxil Fumarate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 25, 2019 Category: Drugs & Pharmacology Source Type: news

Treatment Switch for Hep B Patients With Renal, Bone Risk Treatment Switch for Hep B Patients With Renal, Bone Risk
A change to a different form of tenofovir might lower the risk for adverse bone and renal effects, new research shows, but concerns about other risks are emerging.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Antivirals for Blocking Mother-to-Child Transmission of HBV Antivirals for Blocking Mother-to-Child Transmission of HBV
Is lamivudine as effective as tenofovir disoproxil fumarate for preventing mother-to-child transmission of HBV?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 20, 2019 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Florida Pharmaceutical Products, Inc., Inks Agreement With Qilu To...
Florida Pharmaceutical Products, Inc., will sell, market and distribute Qilu Pharmaceutical Co., Ltd., ANDA for Tenofovir 300mg tablets.(PRWeb March 14, 2019)Read the full story at https://www.prweb.com/releases/florida_pharmaceutical_products_inc_inks_agreement_with_qilu_to_sell_market_and_distribute_tenofovir_300mg_tablets/prweb16141200.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 14, 2019 Category: Pharmaceuticals Source Type: news

Stopping Oral Antiviral Therapy in Chronic Hep B Possible for Some People Stopping Oral Antiviral Therapy in Chronic Hep B Possible for Some People
A new analysis provides insight into what happens after stopping tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients with persistent viral suppression who took the drug for at least eight years.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir   Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 7, 2019 Category: Drugs & Pharmacology Source Type: news

Effect of Hormonal Contraception on Vaginal Tenofovir Effect of Hormonal Contraception on Vaginal Tenofovir
In what ways might contraceptive hormones impact the pharmacokinetics of topically applied tenofovir?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2019 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

MTN researchers begin safety study of a 90-day vaginal ring containing tenofovir
(Microbicide Trials Network) A vaginal ring designed to protect women against both HIV and herpes simplex virus type 2 (HSV-2) is being tested in a new study that aims to determine whether its use for three months is safe. The Phase I study, taking place at three U.S. trial sites, is one of two studies evaluating full 90-day use of the ring, which contains an antiretroviral drug called tenofovir, and the first to enroll participants. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 16, 2019 Category: Infectious Diseases Source Type: news

Four-drug Combo Pill for HIV an Option in Chronic Dialysis Patients Four-drug Combo Pill for HIV an Option in Chronic Dialysis Patients
A daily single-tablet regimen of coformulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide, approved in the U.S. and elsewhere for HIV-1-infected patients with mild-to-moderate chronic kidney disease, may also work well in those with end-stage renal disease on chronic hemodialysis, a new study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

EC Clears Two New HIV Drugs (Pifeltro and Delstrigo) EC Clears Two New HIV Drugs (Pifeltro and Delstrigo)
Pifeltro contains doravirine, a new nonnucleoside reverse transcriptase inhibitor, and Delstrigo is a fixed-dose combination of doravirine, lamivudine, and tenofovir disoproxil fumarate.International Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 1, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news

Temixys (Lamivudine and Tenofovir Disoproxil Fumarate Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 28, 2018 Category: Drugs & Pharmacology Source Type: news

Complera (Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 15, 2018 Category: Drugs & Pharmacology Source Type: news

Switching to RPV/FTC/TAF From RPV/FTC/TDF or EFV/FTC/TDF Switching to RPV/FTC/TAF From RPV/FTC/TDF or EFV/FTC/TDF
Switching to a coformulated regimen containing tenofovir alafenamide may provide additional bone and renal benefits in HIV patients.HIV Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 7, 2018 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Switching From Tenofovir in HIV Patients With Renal Toxicity Switching From Tenofovir in HIV Patients With Renal Toxicity
Might a treatment switch help reverse the nephrotoxic effects associated with tenofovir use?HIV Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 22, 2018 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Tenofovir Beats Entecavir for Preventing Liver Cancer? Tenofovir Beats Entecavir for Preventing Liver Cancer?
An observational study reports that in patients with hepatitis B, tenofovir significantly lowers the risk for liver cancer compared with entecavir.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news